-
Company Profile
![]()
Avadel Pharmaceuticals Plc – Company Profile
Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (narcolepsy), pain, respiratory diseases and diabetes. It’s products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump – derived platform for liquid oral products, and Medusa that enables controlled release of injectables. It sells products in the US and Ireland. The company operates in St. Louis, Missouri and...
Add to Basket -
Sector Analysis
![]()
Narcolepsy: Opportunity Analysis and Forecasts to 2027
Narcolepsy is a chronic sleep disorder characterized by two major symptoms, excessive daytime sleepiness (EDS) and cataplexy. There are two forms of narcolepsy recognized by The International Classification of Sleep Disorders: narcolepsy with cataplexy, also called narcolepsy type 1 (NT1); and narcolepsy without cataplexy, known as narcolepsy type 2 (NT2). NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus, while the cause for NT2 is still unknown and...
-
Product Insights
![]()
Narcolepsy Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Narcolepsy Global Clinical Trials Review, H1, 2016" provides an overview of Narcolepsy clinical trials scenario. This report provides top line data relating to the clinical trials on Narcolepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.